论文信息 - Eighth American Joint Committee on Cancer (AJCC) melanoma classification: Let us reconsider stage III. - 字舞流文

Eighth American Joint Committee on Cancer (AJCC) melanoma classification: Let us reconsider stage III.

A. Hauschild | D. Schadendorf | P. Ascierto | R. Dummer | J. Larkin | J. Schachter | C. Garbe | P. Nathan | J. Grob | A. Daud | C. Robert | P. Lorigan | J. Hansson | O. Hamid | J. Weber | C. Hoeller | A. V. van Akkooi

[1] T. Lotti,et al. Completion dissection or observation for sentinel‐node metastasis in melanoma , 2017, Dermatologic therapy.

[2] Jeffrey E Gershenwald,et al. Melanoma staging: Evidence‐based changes in the American Joint Committee on Cancer eighth edition cancer staging manual , 2017, CA: a cancer journal for clinicians.

[3] P. Ascierto,et al. Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma , 2017, The New England journal of medicine.

[4] A. Hauschild,et al. Adjuvant Dabrafenib plus Trametinib in Stage III BRAF‐Mutated Melanoma , 2017, The New England journal of medicine.

[5] C. Berking,et al. Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial. , 2016, The Lancet. Oncology.